drugset / Trial / NCT01239030

Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD

NCT01239030

Phase 3 Completed 230 enrolled Rhodes Pharmaceuticals, L.P.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This multi-center parallel study is designed to study the efficacy and safety of fixed doses of methylphenidate extended release (ER) capsules of four dose levels compared with a placebo group in pediatric patients with Attention Deficit Hyperactivity Disorder (ADHD) who are between 6 and 18 years old.

Timeline

Start
2010-11
Primary completion
2012-02
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylphenidate Small molecule 10 mg
Subject Methylphenidate Small molecule 15 mg
Subject Methylphenidate Small molecule 20 mg
Subject Methylphenidate Small molecule 40 mg
Subject Methylphenidate Small molecule 50 mg
Subject Methylphenidate Small molecule 60 mg